SANTARUS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY12 | FY11 | FY10 | FY09 | |
|---|---|---|---|---|
| Revenue | $45.9M | $22.8M | $125.4M | $172.5M |
| Operating income | $20.2M | $5.4M | −$18.0M | $34.1M |
| Net income | $627,000 | −$516,000 | −$18.5M | $32.1M |
| Total assets | $163.7M | $114.1M | $96.0M | — |
| Total liabilities | — | — | — | — |
| Equity | $83.0M | $50.1M | $38.0M | $46.9M |
| EPS (diluted) | $0.01 | $-0.01 | $-0.31 | $0.54 |
| Shares out. | 61.2M | 61.1M | 60.0M | 59.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2012- Operating margin
- 44.0%
- Net margin
- 1.4%
- Return on equity
- 0.8%
- Return on assets
- 0.4%
- Return on capital (ROCE)
- 20.7%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $1.35
- Revenue growth (YoY)
- 101.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2012- Accruals / assets
- −21.5%clean
- Piotroski F-Score
- 7/8strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 4 good- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATEDec 4, 2009
- ZEGERIDMar 24, 2006
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · New financial obligation · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJan 2, 2014
- Other material eventNov 12, 2013
- Entered a material agreement · Results of operations · Amended charter or bylaws · Other material eventNov 7, 2013
- Results of operationsAug 6, 2013
- Regulation FD disclosureJul 9, 2013
- Other material eventJun 24, 2013
- Other material eventJun 18, 2013
- Director / officer change · Shareholder voteJun 13, 2013
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.